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Abstract: Previously, we described the link between C-X-C motif chemokine 12 (Cxcl12) gene induction and DNA hypo-
methylation in the absence of poly(ADP-ribose) polymerase 1 (PARP-1). We have now firmly established that demethylation 
is the primary cause of gene induction on the basis of Cxcl12 gene upregulation upon treatment with the demethylating 
agent 5-azacytidine (5-aza). Since the demethylation state of Cxcl12 is favored by PARP-1 absence, we investigated the pres-
ence of ten-eleven translocation (TET) proteins on the Cxcl12 promoter in order to corroborate the relationship between 
the demethylation process and increased gene expression that occurs in the absence of PARP-1. Analysis was performed 
on the promoter region within CpG islands of Cxcl12 from control mouse embryonic fibroblasts (NIH3T3) and PARP-1 
knock-out mouse embryonic fibroblasts (PARP1-/-). The lack of PARP-1 increased the abundance of TET2 on the Cxcl12 
promoter, suggesting that TET-mediated demethylation provoked by the absence of PARP-1 could account for the observed 
increased expression of this chemokine. Deciphering the regulation of DNA (de)methylation factors that control Cxcl12 
expression may provide an additional therapeutic approach in pharmacological interventions where gene switching on or 
off based on targeted stimulation or inhibition is necessary.
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INTRODUCTION
DNA methylation is a covalent modification of 
genomic DNA that occurs predominantly at CG di-
nucleotides (CpG) where DNA methyltransferase 
(DNMTs) enzymes mediate the transfer of a me-
thyl group to the 5-position of cytosines, generating 
5-methylcytosine (5mC), which is assumed to be a 
fifth DNA base [1-3]. Ten-eleven translocation 1-3 
(TET1-3) proteins, members of the DNA hydroxylase 
family, affect the methyl group on 5mC by catalyzing 
the consecutive oxidation of 5mC into 5-hydroxym-
ethylcytosine (5hmC), 5-formylcytosine (5fC) and 
5-carboxylcytosine (5caC) [4,5]. Further, 5caC can 
be replaced by an unmethylated cytosine by thymine-
DNA glycosylase (TDG) via the base excision repair 
(BER) pathway [6]. Hence TET proteins can generate 
both new epigenetic marks (5hmC, 5fC and 5caC) in 
genomic DNA and also reverse the 5mC to the un-
methylated state which comprises the process of active 
DNA demethylation [7,8]. Since DNA (de)methyla-
tion is closely linked to gene expression, it is impor-
tant to explore the regulation of these mechanisms 
when related to various diseases which are character-
ized by aberrant DNA methylation. Poly(ADP-ribose)
polymerase (PARP) enzymes, which catalyze covalent 
attachment of poly-ADP-ribose (PAR) units to accep-
tor proteins (PARylation), take part in the regulation 
of DNA (de)methylation processes [9]. PARP-1 is the 
founding member of PARP family that participates 
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in the production of PAR polymers. Besides PARP-1 
automodification where the enzyme PARylates itself, 
it can also PARylate covalently other target proteins, 
thereby modulating their activities and functions. 
PAR moieties can also bind non-covalently to target 
proteins that expand the number of PARP-1 inter-
acting partners subjected to PARylation [9-11]. The 
link between PARP-1 and TET activity in DNA dem-
ethylation is emerging as a newly discovered role of 
PARP-1 [11].
In our previous study we reported that PARP-1 
promotes DNA methylation and the opposite, that 
lack of PARP-1 is connected with the demethyla-
tion state of Cxcl12 gene; this also corresponds with 
changes in Cxcl12 expression, which tends to increase 
in the absence of PARP-1 [12]. CXCL12, also known 
as stromal cell-derived factor 1 (SDF-1), is a potent 
CXC chemokine produced by different cell types. It is 
involved in the migration of a variety of cells, including 
hematopoietic progenitor and stem cells, endothelial 
cells and most leukocytes [13]. CXCL12 is involved 
in physiological and pathological processes, such as 
development, cell survival, tissue repair and regenera-
tion, as well as cancer [14,15]. The methylation status 
of the Cxcl12 gene plays an important role in tumor 
progression in human carcinogenesis. For example, 
epigenetically-controlled downregulation of the Cxcl12 
by promoter hypermethylation has been detected in 
breast tumors [16] and in osteosarcomas [17], and is 
connected with metastatic potential and poor survival 
prognosis. Hence, the methylation status of Cxcl12 
could be used as a target for therapeutic interventions.
Since we previously found PARP-1 to be a po-
tential upstream player in methylation events that 
modulated Cxcl12 expression, our aim was to examine 
whether a lack of PARP-1 would induce TET enzymes 
to demethylate Cxcl12.
MATERIALS AND METHODS
Cell culture and treatment
The following cell lines were used: mouse embryonic 
fibroblasts, NIH3T3 (ATCC- CRL-1658), and PARP-1 
knock-out (PARP1-/-) cells [18]. The cells were cul-
tured in high glucose Dulbecco’s Modified Eagle’s me-
dium (DMEM) supplemented with 10% fetal bovine 
serum (FBS), L-glutamine and penicillin/streptomycin 
(all cell culture reagents were supplied by Biological 
Industries, Beit Haemek Ltd., Israel). NIH3T3 cells 
were treated with 15 µM 5-azacytidine (5-aza) solu-
bilized in dimethyl sulfoxide (DMSO) for 72 h, with 
the treatment replaced every 24 h. In parallel with the 
5-aza treatment, control NIH3T3 cells were treated 
with DMSO in the same manner.
RNA isolation, reverse transcription and real-
time quantitative PCR (RT-qpcr)
Total RNA was isolated from NIH3T3 cells treated with 
5-aza or DMSO and PARP1-/- cells using the GeneJET 
RNA Purification Kit (Thermo Fisher Scientific, USA). 
Reverse transcription was performed on 1 µg of DNase 
I-treated RNA by the RevertAid First Strand cDNA 
Synthesis Kit (Thermo Fisher Scientific, USA) with 
a mix of oligo(dT)18 and random hexamer primers. 
For RT-qPCR we used QuantStudio 3 Real-Time PCR 
system (Applied Biosystems, Carlsbad, CA, USA) and 
Maxima SYBR Green/ROX qPCR Master Mix (Thermo 
Fisher Scientific, USA). The thermal cycles were as fol-
lows: initial denaturation at 95°C for 10 min and 40 
cycles of two-step PCR at 95°C for 15 s and at 60°C 
for 60 s. Expression of Cxcl12 was estimated relative to 
GAPDH (as an internal control) by the delta Ct method 
(2dCt) with previously published primers [12] (Supple-
mentary Table S1). The obtained data was log2 trans-
formed for statistical testing and statistical significance 
was estimated using ANOVA with Dunnett’s post-hoc 
test used to compare NIH3T3 5-aza-treated and PARP-
/- cells with control NIH3T3 cells mock-treated with 
DMSO. For graphs, mean values and error bars were 
transformed back to the linear scale.
DNA isolation, bisulfite conversion and 
methylation-specific PCR (MSP)
To isolate high molecular weight DNA we used cell 
lysis buffer (2 mM EDTA, 10 mM Tris-HCl pH 7.5, 
10 mM NaCl, 0.5% sodium dodecyl sulfate (SDS)) 
supplemented with 0.04 µg/mL proteinase K. After 
overnight incubation at 55°C, the lysates were ethanol-
precipitated with cold 75 mM sodium acetate dilut-
ed in absolute ethanol. The isolated high molecular 
weight DNA was resuspended in water.
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The EZ-DNA methylation kit (D5002; Zymo 
Research, Orange, CA, USA) was used for bisulfite 
conversion of genomic DNA, as per the provided in-
structions. This bisulfite-converted DNA served as a 
template for MSP analysis of DNA methylation chang-
es. The promoter (1MU), the exon-intron boundary 
(2MU) and part of the intron (3MU) of Cxcl12 were 
analyzed (Fig. 2) with three sets of MSP primers (Sup-
plementary Table S1) that were previously published 
[12]. Each set was comprised of two pairs of primers 
targeted to the same location yet differentiating be-
tween the methylation states, as one pair was com-
plementary to the methylated (M) and the other to 
the unmethylated (U) bisulfite-converted target DNA 
sequence. Separate reactions were set up for each 
primer pair, ensuring that reactions for one sample 
with primers from the same set were always run in 
parallel, within the same PCR run. Each reaction had 
a volume of 10 µL and contained 2 µM primers, 60 ng 
of bisulfite-converted DNA and Maxima SYBR Green/
ROX qPCR Master Mix (Thermo Fisher Scientific, 
USA). The QuantStudio 3 Real-Time PCR system 
(Applied Biosystems, Carlsbad, CA, USA) was used 
for the runs with the following temperature cycling 
profile: initial denaturation at 95°C for 10 min and 40 
cycles of two-step PCR at 95°C for 15 s and 58°C for 
60 s. Finally, to assess the relative level of methylation, 
threshold cycle values (Ct) for M and U primer pairs 
from the same set were used to calculate the methyla-
tion index [19] using the following equation:
2(Ct for U primer pair reaction)-(Ct for M primer pair reaction).
The obtained data was log2 transformed for statis-
tical testing and statistical significance was estimated 
using ANOVA with Dunnett’s post-hoc test to com-
pare the NIH3T3 5-aza-treated and PARP-/- cells with 
control NIH3T3 cells mock-treated with DMSO. For 
graphs, mean values and error bars were transformed 
back to the linear scale.
Chromatin immunoprecipitation (ChIP)
Chromatin immunoprecipitation was performed us-
ing the Pierce™ Magnetic ChIP Kit (Thermo Fisher 
Scientific, USA) according to the protocol. In brief, 
NIH3T3 and PARP-/- chromatin were cross-linked 
with 1% formaldehyde (Zorka Pharma, Serbia) and 
the process was stopped with a glycine solution after 10 
min at room temperature. After extraction, the chro-
matin was digested with 0.005 U/µL micrococcal nu-
clease and sheared on ice by sonication (7 rounds of 20 
s sonication and 30 s rest). Immunoprecipitation was 
performed using Protein A/G Magnetic Beads (USA) 
and the following antibodies: anti-RNA polymerase II 
(RNA pol II) (supplied with the ChIP kit), normal rab-
bit IgG (supplied with the ChIP kit), 5 µg of anti-TET1 
(Millipore Merck, USA) and 5 µg of anti-TET2 (Mil-
lipore Merck, USA). The cross-linking was reversed at 
65°C and the immunoprecipitated samples and sam-
ples containing 10% of total input were treated with 
40 µg proteinase at 65°C for 1.5 h. The abundance of 
the target sequence was assessed by quantitative PCR 
(qPCR) using QuantStudio 3 Real-Time PCR system 
(Applied Biosystems, Carlsbad, CA, USA) and Maxima 
SYBR Green/ROX qPCR Master Mix (Thermo Fisher 
Scientific, USA). Primers (Supplementary Table S1) 
were designed to amplify part of the promotor region 
directly adjacent to the transcription start site (TSS) 
of Cxcl12 (Fig. 2). To quantify the enrichment, first 
the quantity of ChIP and IgG samples was determined 
from a standard curve generated with qPCR data of 10-
fold dilution series of the 10% total input samples. En-
richment was calculated by normalizing to IgG sample 
quantity and fold enrichment was reported relative to 
the corresponding NIH3T3 samples (immunoprecipi-
tated by the same antibody) from the same experiment. 
The experiment was repeated twice.
Co-immunoprecipitation (IP)
NIH3T3 and PARP-/- cells were lysed in ice-cold 
ProteoJET™ Mammalian Cell Lysis Reagent (Thermo 
Fisher Scientific, USA), supplemented with a protease 
inhibitor cocktail, for 30 min at 4°C. Cell lysates (300 
µg) were precleared by incubation with Protein A/G 
agarose-coupled beads (Santa Cruz Biotechnology, 
Santa Cruz, CA, USA). The precleared lysate was in-
cubated overnight at 4°C on a tube rotator with 2 µg 
of anti-TET2 antibody (Millipore Merck, USA), which 
was followed by the addition of protein A/G agarose-
coupled beads (Santa Cruz Biotechnology, Santa Cruz, 
CA, USA) and further incubation at 4°C for 4 h. The 
agarose beads were pelleted and washed 5 times with 
a buffer containing 50 mM Tris-HCl, pH 8.0, 150 mM 
NaCl, 1% Triton X-100, 0.2 mM phenyl methyl sulfo-
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nyl fluoride (PMSF) and a protease inhibitor cocktail. 
Proteins were eluted from the beads by boiling in a 
sample buffer (125 mM Tris-HCl, pH 6.8, 4% SDS, 20% 
glycerol, 100 mM dithiothreitol, 0.02% bromophenol 
blue), separated by 7% sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE) alongside 
70 µg of proteins from the NIH3T3 lysate. The proteins 
were electrotransferred onto polyvinylidene difluoride 
(PVDF) membranes and analyzed by immunoblotting.
Immunoblot analysis
NIH3T3 and PARP-/- cells were lysed in ice-cold 
RIPA buffer (Sigma Aldrich, USA) supplemented 
with a protease inhibitor cocktail for 30 min at 4°C. 
Equal amounts of cell lysates were separated by 12% 
SDS-PAGE and electrotransferred onto PVDF mem-
branes. Immunoblotting for lysates or IP samples was 
performed by overnight incubation at 4°C with anti-
PARP-1 (H-250, Santa Cruz Biotechnology, Santa Cruz, 
CA, USA) or anti-TET2 primary antibodies (Millipore 
Merck, USA) and anti-GAPDH (FL-335, Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) as loading con-
trol for lysates. This was followed by incubation with 
horseradish peroxidase‐conjugated anti‐rabbit second-
ary antibody at room temperature for 1 h. Staining was 
performed by the enhanced chemiluminescence detec-
tion system (Santa Cruz Biotechnology, Santa Cruz, 
CA, USA) according to the manufacturer’s instructions.
RESULTS
Cxcl12 expression was increased in 5-aza-treated 
NIH3T3 and PARP-/- cells
Treatment of NIH3T3 cells with the demethylating 
agent 5-aza induced a higher level of Cxcl12 expres-
sion as measured by real-time PCR. Treated NIH3T3 
cells showed on average a 5.5-fold increase compared 
to control NIH3T3 cells, while PARP-/- cells showed 
an even greater increase of 2x105-fold compared to the 
control (Fig. 1). Both observed increases were statisti-
cally significant (p5aza=0.02 and pPARP-/-=1.9x10-8).
Methylation changes of Cxcl12 in 5-aza-treated 
NIH3T3 and PARP-/- cells
As previously established [12], murine Cxcl12 gene 
has a CpG island that spans a part of its promoter, first 
exon and part of the first intron (Fig. 2). The methyla-
tion changes of Cxcl12 on these regions were exam-
ined as follows: amplicons analyzed by MSP covered 
8 CpGs in the promoter, 23 CpGs at the exon-intron 
boundary and 8 CpGs in the intron region. In accord-
ance with the changes in expression, we observed that 
both the treatment of NIH3T3 cells with 5-aza and 
the absence of PARP-1 resulted in demethylation of 
Cxcl12. Cells treated with 5-aza exhibited a statistically 
significant decrease in methylation, on average 45.4-
Fig. 1. Relative expression level of Cxcl12 in control NIH3T3 cells 
(mock-treated with DMSO), NIH3T3 cells treated with 15 µM 
5-aza and PARP−/− cells (n = 5) measured by RT-qPCR. Statistical 
significance is reported for the comparison of NIH3T3 5-aza-
treated and PARP-/- cells to the control NIH3T3 cells. Results 
are presented as the mean±standard error of the mean, *p≤0.05, 
***p ≤ 0.001, n‐number of independent experiments.
Fig. 2. Schematic representation of murine Cxcl12 and positions of primers used for MSP and ChIP qPCR.
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fold in the promoter region (p=1x10-6) and 4.3-fold 
at the exon-intron boundary (p=3.9x10-4), while the 
intron region was not significantly affected (Fig. 3). 
PARP-/- cells showed a significantly higher level of 
demethylation (Fig. 3). Compared to NIH3T3 cells, 
methylation in PARP-/- cells was decreased 1032.4-
fold in the promoter (p=3.6x10-8), 1002.4-fold in the 
exon-intron boundary (p=3.1x10-8) and even 285.3-
fold in the intron region (p=5.2x10-8).
The level of TET2 at the Cxcl12 promoter is 
higher in the absence of PARP-1
ChIP analysis showed that TET proteins interact with 
the Cxcl12 promoter. Control ChIP experiments per-
formed with an anti- RNA pol II antibody confirmed 
that RNA pol II was more abundantly present (on aver-
age 5.7-fold more) on the Cxcl12 promoter of PARP-/- 
than of NIH3T3 cells (Fig. 4). This result was in agree-
ment with the Cxcl12 expression profile in these cells. 
The results for TET1 were deemed inconclusive as no 
consistent change was observed (data not shown). We 
therefore focused on TET2, as it was consistently pre-
sent in higher abundance (on average 1.32-fold) on 
the analyzed region of the Cxcl12 promoter in PARP-
/- when compared to NIH3T3 cells (Fig. 4).
TET2 interacts with PARP-1
Western-blot analysis confirmed the absence of 
PARP-1 in PARP-/- cells and showed higher levels of 
TET2 isoforms (223 kDa and 130 kDa) in PARP-/- as 
compared to NIH3T3 cells (Fig. 5A). Results of IP 
analysis showed that TET2 was successfully immu-
noprecipitated from NIH3T3 cell lysates and that it 
co-precipitated PARP-1, confirming their interaction 
in cellulo (Fig. 5B).
DISCUSSION
In the past decade, much attention has been focused 
on the role of epigenetic alterations in cancer progres-
sion [20]. The increased metastatic potential in some 
types of cancers, such as colon, mammary and breast 
carcinomas, was shown to be associated with epige-
netic silencing of Cxcl12 [16,21,22]. Furthermore, 
considering the ability of CXCL12 to stimulate the 
growth and survival of pancreatic β-cells, the tran-
Fig. 3. Methylation levels of different parts of Cxcl12 of control 
NIH3T3 cells (mock-treated with DMSO), NIH3T3 cells treated 
with 15 µM 5-aza and PARP−/− cells measured by methylation‐
specific PCR (MSP) (n = 4). Under each graph, the amplicon 
sequence is represented with highlighted CG dinucleotides. Statis-
tical significance is reported for the comparison of NIH3T3 5-aza-
treated and PARP-/- cells to the control NIH3T3 cells. Results 
are presented as the mean±standard error of the mean, *p≤0.05, 
***p≤0.001, n‐number of independent experiments.
Fig. 4. ChIP-qPCR analysis of RNA pol II and TET2 occupancy 
at the Cxcl12 promoter in NIH3T3 and PARP-/- cell lines (n=2). 
Results are presented as the mean±standard error of the mean.
Fig. 5. A – Immunoblot analysis performed with anti-TET2, anti-
PARP-1 and anti-GAPDH (loading control) antibodies, on lysates 
isolated from NIH3T3 and PARP-/- cell lines. B - Immunoprecipi-
tation of TET2 from NIH3T3 cells analyzed by immunoblotting 
with anti-TET2 and anti-PARP-1. Successful immunoprecipitation 
of TET2 was confirmed as well as coprecipitation of PARP-1 with 
TET2. IP – immunoprecipitation.
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scriptional regulation of this chemokine could provide 
an approach for diabetes treatment [23]. Hence, thera-
pies that target CXCL12 expression via de/methylation 
possess the potential for therapeutic interventions, 
and identification of factors that affect the methyla-
tion status of this chemokine is of great importance.
In this study we verified that PARP-1 affected the 
methylation status of Cxcl12 whereby the absence of 
PARP-1 promoted TET2 involvement on the Cxcl12 
promoter, linking TET-dependent demethylation and 
increased gene expression in the absence of PARP-1. 
Restored expression of Cxcl12 after treatment with 
5-aza, one of the most frequently used demethylating 
agents that inhibits DNMTs [24,25], confirmed the 
epigenetic transcriptional silencing of Cxcl12. While 
treatment with 5-aza is presumably based on inactiva-
tion of methylation due to rapid loss of DNMT activity, 
our previous results indicated that in PARP-/- cells the 
promotion of TET-dependent active demethylation 
occurs rather than DNMT-related suppressed methyla-
tion [12]. We assumed that this scenario also occurs in 
the Cxcl12 gene; however, a direct link between TET-
mediated DNA demethylation and the transcriptional 
output is difficult to establish because of the existence 
of global and locus-specific effects that are difficult to 
discern [26]. Demethylation of the Cxcl12 promoter 
region was expected as it was already established that 
the Cxcl12 gene is exposed to epigenetic regulation by 
methylation of cytosine in CpG dinucleotides located 
in the promoter sequence [27-29]. In the intron region 
there was no statistically significant decrease in meth-
ylation in NIH3T3 cells treated with 5-aza, whereas 
a significant decrease was observed in PARP-/- cells. 
This points to the stronger potential for demethyla-
tion of Cxcl12 in PARP-/- compared to NIH3T3 cells 
treated with 5-aza, which could have also contributed 
to the higher increase in Cxcl12 expression.
Although the absence of PARP-1 in the demethyl-
ation event is clear, it remains to be elucidated whether 
the TETs are responsible for the loss of methylation. 
Our previous results suggested that PARP-1 could be 
involved in demethylation as significant increases in 
both TET1 and TET2 expression were detected in the 
absence of PARP-1 [12]; herein we showed that the 
lack of PARP-1 increased TET2 occupancy on the 
Cxcl12 promoter. Furthermore, according to the ob-
tained result there was no clear increase in TET1 on 
the Cxcl12 promoter (result not shown); however, this 
does not rule out the possibility that TET1 was also 
affected by the absence of PARP-1 for recruitment and 
demethylation events on the Cxcl12 promoter. This 
assumption needs further validation.
TET proteins preferentially bind to DNA con-
taining unmodified cytosine [30-32]. While TET1 is 
recruited to genomic target sites through direct bind-
ing of CXXC domains to CpG-rich oligonucleotides 
[3,33,34], TET2 lacks the CXXC DNA-binding do-
main, thus it is more likely that its recruitment on a 
specific gene is mediated by interactions with other 
DNA-binding factors [35]. It was found that TET2 in-
teracts with IDAX protein whose CXXC domain binds 
to unmethylated CpG dinucleotides in the promoter 
but in a sequence-nonspecific manner [31]. A very 
recent report described the mechanism for targeting 
TET2 to specific promoters [36]. It was proposed that 
transcriptional co-activator SMAD nuclear interacting 
protein 1 (SNIP1) bridges TET2 to bind to a sequence-
specific DNA-binding factor c-MYC, thus facilitating 
the recruitment of TET2 to regulate c-MYC target 
genes by promoting DNA demethylation at the pro-
moters [36]. In addition, it is well established that the 
posttranslational modification, monoubiquitylation, 
which is catalyzed by CRL4VprBP E3 ligase, promotes 
the DNA binding of TET2 by stabilizing the conforma-
tion of TET2 complexed with DNA (where the mon-
oubiquitylation site directly contacts the DNA) [32,37].
The activity of TETs can be modulated by metabo-
lites, cofactors and several post-translational modi-
fications [35]. Our previous results marked TETs as 
potentially important factors in Cxcl12 expression in 
the absence of PARP-1. This was supported by the 
detected tendency of Cxcl12 expression to increase 
in the presence of TET activator (vitamin C), and to 
decrease upon treatment with the TET inhibitor di-
methyloxaloylglycine (DMOG) in PARP-/- cells [12]. 
The findings presented herein encourage us to assume 
that the lack of PARP-1 was responsible for the in-
creased recruitment of TET2 to the Cxcl12 promoter, 
which is a prerequisite step that leads to augmented 
activity and demethylation events.
As interactions between TET2 and PARP-1 in hu-
man embryonic kidney 293T (HEK293T) cells were 
reported [38], it was expected that these proteins estab-
lish interactions in NIH3T3 cells, as we have showed. 
We assumed that these interactions could have an in-
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hibitory role on the catalytic activity of TETs, since our 
previous results showed a global increase in TET ex-
pression/activity in the absence of PARP-1 [12]. Hence 
the catalytic activation of TET enzymes together with 
the increased recruitment of TET2 in the absence of 
PARP-1 could have contributed to the local demeth-
ylation event on the Cxcl12 promoter, accounting for 
its induced expression. This is in collision with some 
literature data showing that inhibition of PARylation 
suppresses the production of 5hmC by TET proteins 
and consequently region-specific demethylation [39]. 
Nevertheless, the role of PARP-1 in demethylation and 
its impact on TET activity was recently reviewed and 
it was pointed out that data implicating PARP/TET 
interplay in the regulation of (de)methylation that can 
produce opposite effects, resulting in either increased 
or decreased 5mC-hydroxylase activity, is still emerging 
[11]. Consistent with this view is the observation that 
after inhibition of PARylation, aside from a number of 
hypermethylated genes, several genes were also found 
to be hypomethylated [40].
CONCLUSION
Enrichment of the Cxcl12 promoter with TET2, to-
gether with the previously described overall increased 
expression and activity of TETs in the absence of 
PARP-1, highlight the connection of PARP-1 and gene 
expression through (de)methylation events, and sup-
port the inhibitory role of PARP-1 in demethylation, 
which explains the increased expression of Cxcl12. 
Future research should focus on exploring the effect 
of PARP activity (not only its presence) on Cxcl12 
expression and on epigenetic events as this could en-
hance the efficacy of PARP inhibitors in their poten-
tial clinical translation.
Funding: This work was supported by the Alexander von Hum-
boldt foundation, program for funding a Research Group Linkage 
(to MV and TJ - 2015/2016). Financial support was also provided 
by the Ministry of Education, Science and Technological Develop-
ment of the Republic of Serbia (Project No. 173020).
Acknowledgments: The authors are very grateful to Dr. Valérie 
Schreiber (Département Intégrité du Génome, UMR7175-LC1 
CNRS, Ecole Supérieure de Biotechnologie de Strasbourg, Illkirch 
Cedex, France) for providing the PARP-1 knock-out cells.
Author contributions: AU and MV designed the study; AT, JR 
and MS performed the experiments; MĐ, MM and JAJ analyzed 
the data statistically; AT and AU wrote the manuscript; TJ, SD, 
NG, and GP critically reviewed the manuscript.
Conflict of interest disclosure: The authors declare no conflict 
of interest.
REFERENCES
1.  Goll MG, Bestor TH. Eukaryotic cytosine methyltransferases. 
Annu Rev Biochem. 2005;74(1):481-514. 
2.  Bernstein BE, Meissner A, Lander ES. The mammalian epig-
enome. Cell. 2007;128(4):669-81. 
3.  Williams K, Christensen J, Helin K. DNA methylation: 
TET proteins-guardians of CpG islands? EMBO Rep. 
2012;13(1):28-35. 
4.  Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, 
Brudno Y, Agarwal S, Iyer LM, Liu DR, Aravind L, Rao A. 
Conversion of 5-methylcytosine to 5-hydroxymethylcyto-
sine in mammalian DNA by MLL partner TET1. Science. 
2009;324(5929):930-5. 
5.  Ito S, Shen L, Dai Q, Wu SC, Collins LB, Carolina N, Hill 
C, Swenberg J a, He C, Zhang Y. Tet proteins can convert 
5-methylcytosine to 5-formylcytosine and 5-carboxylcyto-
sine. Science. 2011;333(6047):1300-3. 
6.  He Y, Li B-Z, Li Z, Liu P, Wang Y, Tang Q, Ding J, Jia Y, Chen 
Z, Li L, Sun Y, Li X, Dai Q, Song C-X, Zhang K, He C, Xu G-L. 
Tet-mediated formation of 5-carboxylcytosine and its excision 
by TDG in mammalian DNA. Science. 2011;333(6047):1303-7. 
7.  Tan L, Shi YG. Tet family proteins and 5-hydroxymeth-
ylcytosine in development and disease. Development. 
2012;139(11):1895-902. 
8.  Kong L, Tan L, Lv R, Shi Z, Xiong L, Wu F, Rabidou K, Smith 
M, He C, Zhang L, Qian Y, Ma D, Lan F, Shi Y, Shi YG. A 
primary role of TET proteins in establishment and mainte-
nance of De Novo bivalency at CpG islands. Nucleic Acids 
Res. 2016;44(18):8682-92. 
9.  Caiafa P, Guastafierro T, Zampieri M. Epigenetics: poly(ADP-
ribosyl)ation of PARP-1 regulates genomic methylation pat-
terns. FASEB J. 2009;23(3):672-8. 
10.  Krishnakumar R, Kraus WL. The PARP side of the nucleus: 
molecular actions, physiological outcomes, and clinical tar-
gets. Mol Cell. 2010;39(1):8-24. 
11.  Ciccarone F, Zampieri M, Caiafa P. PARP1 orchestrates epi-
genetic events setting up chromatin domains. Semin Cell Dev 
Biol. 2017;63:123-34. 
12.  Tolić A, Grdović N, Dinić S, Rajić J, Đorđević M, Sinadinović 
M, Arambašić Jovanović J, Mihailović M, Poznanović G, 
Uskoković A, Vidaković M. Absence of PARP-1 affects Cxcl12 
expression by increasing DNA demethylation. J Cell Mol 
Med. 2019;00:1-9. 
13.  Janssens R, Struyf S, Proost P. The unique structural 
and functional features of CXCL12. Cell Mol Immunol. 
2018;15(4):299-311. 
14.  Ratajczak MZ, Zuba-Surma E, Kucia M, Reca R, Wojakowski 
W, Ratajczak J. The pleiotropic effects of the SDF-1-CXCR4 
axis in organogenesis, regeneration and tumorigenesis. Leu-
kemia. 2006;20(11):1915-24. 
462 Arch Biol Sci. 2019;71(3):455-462
15.  Liu Z, Habener JF. Stromal cell-derived factor-1 promotes 
survival of pancreatic beta cells by the stabilisation of 
beta-catenin and activation of transcription factor 7-like 2 
(TCF7L2). Diabetologia. 2009;52(8):1589-98. 
16.  Ramos EAS, Camargo AA, Braun K, Slowik R, Cavalli IJ, 
Ribeiro EMSF, Pedrosa F de O, de Souza EM, Costa FF, Klas-
sen G. Simultaneous CXCL12 and ESR1 CpG island hyper-
methylation correlates with poor prognosis in sporadic breast 
cancer. BMC Cancer. 2010;10(1):23. 
17.  Li B, Wang Z, Wu H, Xue M, Lin P, Wang S, Lin N, Huang 
X, Pan W, Liu M, Yan X, Qu H, Sun L, Li H, Wu Y, Teng W, 
Wang Z, Zhou X, Chen H, Poznansky MC, Ye Z. Epigenetic 
regulation of CXCL12 plays a critical role in mediating tumor 
progression and the immune response in osteosarcoma. Can-
cer Res. 2018;78(14):3938-53. 
18.  de Murcia JM, Niedergang C, Trucco C, Ricoul M, Dutril-
laux B, Mark M, Oliver FJ, Masson M, Dierich A, LeMeur 
M, Walztinger C, Chambon P, de Murcia G. Requirement 
of poly(ADP-ribose) polymerase in recovery from DNA 
damage in mice and in cells. Proc Natl Acad Sci U S A. 
1997;94(14):7303-7. 
19.  Akirav EM, Lebastchi J, Galvan EM, Henegariu O, Akirav M, 
Ablamunits V, Lizardi PM, Herold KC. Detection of cell death 
in diabetes using differentially methylated circulating DNA. 
Proc Natl Acad Sci. 2011;108(47):19018-23. 
20.  Jones PA, Baylin SB. The fundamental role of epigenetic 
events in cancer. Nat Rev Genet. 2002;3(6):415-28. 
21.  Wendt MK, Cooper AN, Dwinell MB. Epigenetic silencing 
of CXCL12 increases the metastatic potential of mammary 
carcinoma cells. Oncogene. 2008;27(10):1461-71. 
22.  Zhou W, Jiang Z, Liu N, Xu F, Wen P, Liu Y, Zhong W, Song X, 
Chang X, Zhang X, Wei G, Yu J. Down-regulation of CXCL12 
mRNA expression by promoter hypermethylation and its 
association with metastatic progression in human breast 
carcinomas. J Cancer Res Clin Oncol. 2009;135(1):91-102. 
23.  Vidaković M, Grdović N, Dinić S, Mihailović M, Uskoković 
A, Arambašić Jovanović J. The Importance of the CXCL12/
CXCR4 Axis in Therapeutic Approaches to Diabetes Mellitus 
Attenuation. Front Immunol. 2015;6:403. 
24.  Christman JK, Mendelsohn N, Herzog D, Schneiderman N. 
Effect of 5-azacytidine on differentiation and DNA methyla-
tion in human promyelocytic leukemia cells (HL-60). Cancer 
Res. 1983;43(2):763-9. 
25.  Christman JK. 5-Azacytidine and 5-aza-2ʹ-deoxycytidine as 
inhibitors of DNA methylation: mechanistic studies and their 
implications for cancer therapy. Oncogene. 2002;21(35):5483-95. 
26.  Verma N, Pan H, Doré LC, Shukla A, Li Q V, Pelham-Webb 
B, Teijeiro V, González F, Krivtsov A, Chang C-J, Papapetrou 
EP, He C, Elemento O, Huangfu D. TET proteins safeguard 
bivalent promoters from de novo methylation in human 
embryonic stem cells. Nat Genet. 2018;50(1):83-95. 
27.  Mori T, Kim J, Yamano T, Takeuchi H, Huang S, Umetani N, 
Koyanagi K, Hoon DSB. Epigenetic Up-regulation of C-C Che-
mokine Receptor 7 and C-X-C Chemokine Receptor 4 Expres-
sion in Melanoma Cells. Cancer Res. 2005;65(5):1800-7. 
28.  Wendt MK, Johanesen PA, Kang-Decker N, Binion DG, Shah 
V, Dwinell MB. Silencing of epithelial CXCL12 expression by 
DNA hypermethylation promotes colonic carcinoma metas-
tasis. Oncogene. 2006;25(36):4986-97. 
29.  Kubarek Ł, Jagodzinski PP. Epigenetic up-regulation of 
CXCR4 and CXCL12 expression by 17 β-estradiol and tamox-
ifen is associated with formation of DNA methyltransferase 
3B4 splice variant in Ishikawa endometrial adenocarcinoma 
cells. FEBS Lett. 2007;581(7):1441-8. 
30.  Xu Y, Xu C, Kato A, Tempel W, Abreu JG, Bian C, Hu Y, Hu D, 
Zhao B, Cerovina T, Diao J, Wu F, He HH, Cui Q, Clark E, Ma 
C, Barbara A, Veenstra GJC, Xu G, Kaiser UB, Liu XS, Sugrue 
SP, He X, Min J, Kato Y, Shi YG. Tet3 CXXC domain and 
dioxygenase activity cooperatively regulate key genes for Xen-
opus eye and neural development. Cell. 2012;151(6):1200-13. 
31.  Ko M, An J, Bandukwala HS, Chavez L, Aijö T, Pastor WA, 
Segal MF, Li H, Koh KP, Lähdesmäki H, Hogan PG, Aravind 
L, Rao A. Modulation of TET2 expression and 5-methylcyto-
sine oxidation by the CXXC domain protein IDAX. Nature. 
2013;497(7447):122-6. 
32.  Nakagawa T, Lv L, Nakagawa M, Yu Y, Yu C, D’Alessio AC, 
Nakayama K, Fan H-Y, Chen X, Xiong Y. CRL4(VprBP) E3 
ligase promotes monoubiquitylation and chromatin binding 
of TET dioxygenases. Mol Cell. 2015;57(2):247-60. 
33.  Zhang H, Zhang X, Clark E, Mulcahey M, Huang S, Shi YG. 
TET1 is a DNA-binding protein that modulates DNA meth-
ylation and gene transcription via hydroxylation of 5-meth-
ylcytosine. Cell Res. 2010;20(12):1390-3. 
34.  Xu Y, Wu F, Tan L, Kong L, Xiong L, Deng J, Barbera AJ, 
Zheng L, Zhang H, Huang S, Min J, Nicholson T, Chen T, 
Xu G, Shi Y, Zhang K, Shi YG. Genome-wide regulation of 
5hmC, 5mC, and gene expression by Tet1 hydroxylase in 
mouse embryonic stem cells. Mol Cell. 2011;42(4):451-64. 
35.  Rasmussen KD, Helin K. Role of TET enzymes in DNA 
methylation , development , and cancer. Genes Dev. 
2016;30(7):733-50. 
36.  Chen L-L, Lin H-P, Zhou W-J, He C-X, Zhang Z-Y, Cheng 
Z-L, Song J-B, Liu P, Chen X-Y, Xia Y-K, Chen X-F, Sun R-Q, 
Zhang J-Y, Sun Y-P, Song L, Liu B-J, Du R-K, Ding C, Lan F, 
Huang S-L, Zhou F, Liu S, Xiong Y, Ye D, Guan K-L. SNIP1 
recruits TET2 to regulate c-MYC target genes and cellular 
DNA damage response. Cell Rep. 2018;25(6):1485-1500.e4. 
37.  Hu L, Li Z, Cheng J, Rao Q, Gong W, Liu M, Shi YG, Zhu 
J, Wang P, Xu Y. Crystal structure of TET2-DNA com-
plex: insight into TET-mediated 5mC oxidation. Cell. 
2013;155(7):1545-55. 
38.  Müller U, Bauer C, Siegl M, Rottach A, Leonhardt H. TET-
mediated oxidation of methylcytosine causes TDG or NEIL 
glycosylase dependent gene reactivation. Nucleic Acids Res. 
2014;42(13):8592-604. 
39.  Fujiki K, Shinoda A, Kano F, Sato R, Shirahige K, Murata M. 
PPARγ-induced PARylation promotes local DNA demethyl-
ation by production of 5-hydroxymethylcytosine. Nat Com-
mun. 2013;4:2262. 
40.  Nalabothula N, Al-jumaily T, Eteleeb AM, Flight RM, 
Xiaorong S, Moseley H, Rouchka EC, Fondufe-Mittendorf 
YN. Genome-wide profiling of PARP1 reveals an interplay 
with gene regulatory regions and DNA methylation. PLoS 
One. 2015;10(8):e0135410.
Supplementary Data
Supplementary Table S1. 
Аvailable at: http://serbiosoc.org.rs/NewUploads/Uploads/Tolic%20
et%20al_4152_Supplementary%20Table%20S1.pdf 
